Market Overview

UPDATE: Oppenheimer Downgrades Corcept Therapeutics to Perform on Disappointing Sales

Related CORT
Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy
Mid-Day Market Update: Conatus Jumps Following Announcement of Licensing Deal With Novartis; Sucampo Shares Slide

Oppenheimer reduced its rating on Corcept Therapeutics (NASDAQ: CORT) from Outperform to Market Perform.

Oppenheimer commented, "On 10/31 Corcept reported 3Q12 results and provided an update on the commercial launch of Korlym, its European strategy and clinical development initiatives. Revenues in 3Q were $1.1M, significantly below our estimates of $3M. It is not clear to us why the sales ramp is so slow, and our back-of-the-envelope calculations suggest that the majority of current patients are former clinical trial participants. Based on Korlym's disappointing launch, we believe that our prior estimates for this drug were incorrect. At this time, it is not clear when Corcept may become cashflow break-even."

Corcept Therapeutics closed at $2.24 on Thursday.

Latest Ratings for CORT

Feb 2017Ladenburg ThalmannInitiates Coverage OnBuy
Dec 2015Janney CapitalInitiates Coverage onBuy
Apr 2015FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for CORT
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (CORT)

View Comments and Join the Discussion!